Alessandro M Vannucchi
Alessandro M Vannucchi
The clinical course of the classic myeloproliferative neoplasms (MPNs) is burdened by an increased rate of cardiovascular events, which are the major cause of mortality. Age and history of thrombosis are the criteria used to stratify patien...
Ruben A Mesa
Ruben A Mesa
Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. Cure is potentially achievable...
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? [0.03%]
来那度胺治疗骨髓增生异常综合征：一种促红细胞生成素刺激剂，还是更多？
Rami S Komrokji,Jeffrey E Lancet,Alan F List
Rami S Komrokji
Anemia remains the most challenging clinical manifestation to treat in patients with lower-risk myelodysplastic syndromes (MDS). Erythropoiesis-stimulating agents are widely used to treat anemia in such patients, but less than one third res...
High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond [0.03%]
高危骨髓增生异常综合征的治疗：化疗、移植及其他疗法
Usama Gergis,Usama Wissa
Usama Gergis
Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite ...
Rifca Le Dieu,John G Gribben
Rifca Le Dieu
Although there have been no randomized trials comparing the outcome of stem cell transplantation (SCT) with standard chemotherapy for patients with chronic lymphocytic leukemia (CLL), increasingly, both autologous and allogeneic SCT approac...
Neil E Kay,Tait D Shanafelt
Neil E Kay
Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic info...
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate [0.03%]
关于聚乙二醇化干扰素阿尔法或甲磺酸伊马替尼治疗真性红细胞增多症的疗效更新研究报告
Richard T Silver
Richard T Silver
Polycythemia vera is a myeloproliferative disease, which, if untreated, leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis, anemia, and splenomegaly. Two newly available drugs, interferon alfa and imatinib...
Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia [0.03%]
骨髓纤维症造血细胞移植
William J Hogan,Mark R Litzow,Ayalew Tefferi
William J Hogan
Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythe...
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia [0.03%]
骨髓纤维瘤和髓外造血的常规及实验性药物治疗
Ruben A Mesa,Alfonso Quintás-Cardama,Srdan Verstovsek
Ruben A Mesa
Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature dea...
Peter-D Jensen
Peter-D Jensen
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by ineffective hematopoiesis in one or more cell lines, resulting in insufficient bone marrow function. For most patients with MDS, sup...